Three Nights Without Cannabis Disrupted Sleep. Extended-release Zolpidem Blunted Much of It.

Within-subject, placebo-controlled crossover. Twenty daily cannabis users alternated between periods of ad libitum cannabis use and short abstinence windows of three days. During one abstinence period they received placebo at bedtime, and during the other they received extended-release zolpidem at bedtime. Each day included overnight polysomnography to quantify sleep stages and efficiency, subjective sleep ratings, and next-day cognitive testing. The abstract does not report dose, setting, or country.

Sleep disturbance is one of the most common withdrawal symptoms reported by regular cannabis users. This study moved past self-report to measure sleep with polysomnography during early abstinence and tested whether a standard hypnotic changed those signals.

Objective sleep data matched what many users describe during early abstinence: shorter, more fragmented nights and changes that look like REM rebound. The hypnotic tested here countered part of that pattern and did so without measurable next-day impairment in this small sample. The trial did not track outcomes beyond three nights, so it cannot speak to how long sleep disruption lasts, whether sleep normalizes on its own, or whether altering sleep during withdrawal changes craving, mood, or return-to-use patterns. It also cannot assess uncommon adverse effects or the impact of repeated or longer hypnotic use.

Small sample (N=20). Only three nights of abstinence per condition, so no insight into longer withdrawal courses. No dose information for zolpidem in the abstract. Cannabis potency, product type, and timing of last use were not reported. Potential order or carryover effects are not detailed. Outcomes were limited to sleep architecture, subjective ratings, and short next-day cognitive tests, not clinical endpoints like craving or return to cannabis use.